…
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Innovotech Inc (IOT.V) is limited; the company is listed on the TSX Venture Exchange and detailed operating descriptions and filings are not readily available in broad public sources. Because available information is sparse, major long-term growth drivers are unclear and investors should monitor company filings and operational updates to assess prospects.
Key investment risks include lack of transparent disclosures, low trading liquidity, execution and financing risk typical of small-cap TSXV issuers and potential regulatory or operational uncertainties.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 0.09M | 0.21M | -0.16M | -0.14M | 0.37M |
| Minority interest | 0.01M | 0.01M | 0.00M | - | - |
| Net income | 0.09M | 0.22M | -0.16M | -0.14M | 0.37M |
| Selling general administrative | 2.27M | 1.01M | 0.69M | 0.83M | 0.82M |
| Gross profit | 2.40M | 1.11M | 0.48M | 0.78M | 1.12M |
| Reconciled depreciation | 0.14M | 0.06M | 0.08M | 0.11M | 0.07M |
| Ebit | - | - | - | - | 0.27M |
| Ebitda | - | - | - | -0.02M | 0.44M |
| Operating income | 0.02M | 0.05M | -0.38M | -0.14M | 0.27M |
| Interest expense | 0.03M | 0.01M | 0.00M | 0.01M | 0.00M |
| Tax provision | 0.00M | - | - | - | - |
| Interest income | 0.01M | 0.00M | 0.01M | 0.01M | 0.02M |
| Net interest income | -0.02M | -0.01M | 0.01M | 0.00M | 0.01M |
| Total revenue | 4.53M | 2.19M | 1.18M | 1.13M | 1.48M |
| Total operating expenses | 4.51M | 2.15M | 1.56M | 1.27M | 1.21M |
| Cost of revenue | 2.14M | 1.08M | 0.70M | 0.35M | 0.36M |
| Total other income expense net | 0.09M | 0.17M | 0.21M | - | 0.09M |
| Net income from continuing ops | 0.09M | 0.21M | -0.16M | -0.14M | 0.37M |
| Net income applicable to common shares | - | - | - | - | 0.37M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4.43M | 3.22M | 1.22M | 1.22M | 1.43M |
| Intangible assets | 0.47M | 0.54M | 0.16M | - | - |
| Total liab | 0.78M | 0.60M | 0.22M | 0.17M | 0.26M |
| Total stockholder equity | 3.60M | 2.57M | 0.93M | 1.06M | 1.18M |
| Other current liab | 0.07M | 0.07M | - | - | 0.03M |
| Common stock | - | - | - | - | 7.70M |
| Capital stock | 9.93M | 8.84M | 7.70M | 7.70M | 7.70M |
| Retained earnings | -8.23M | -8.32M | -8.55M | -8.39M | -8.26M |
| Cash | 1.62M | 0.73M | 0.16M | 0.47M | 0.42M |
| Total current liabilities | 0.52M | 0.42M | 0.18M | 0.17M | 0.22M |
| Other stockholder equity | - | - | - | - | 0.16M |
| Property plant equipment | - | - | - | - | 0.23M |
| Total current assets | 3.02M | 1.68M | 0.57M | 0.83M | 0.99M |
| Long term investments | - | 0.50M | 0.33M | 0.21M | - |
| Net tangible assets | - | - | - | - | 1.18M |
| Short term investments | - | 0.00M | 0.07M | 0.08M | 0.07M |
| Net receivables | 0.51M | 0.54M | 0.20M | 0.18M | 0.38M |
| Long term debt | 0.16M | - | - | - | - |
| Inventory | 0.19M | 0.13M | 0.07M | 0.04M | 0.06M |
| Accounts payable | 0.38M | - | - | - | 0.10M |
| Non current assets total | 1.41M | 1.54M | 0.65M | 0.40M | 0.44M |
| Capital lease obligations | - | - | 0.00M | 0.04M | 0.12M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.55M | -0.49M | -0.04M | -0.07M | -0.06M |
| Change to liabilities | - | - | - | - | -0.02M |
| Total cashflows from investing activities | - | - | - | - | -0.06M |
| Net borrowings | 0.20M | 0.00M | -0.04M | - | -0.07M |
| Total cash from financing activities | 0.88M | 1.14M | -0.04M | -0.09M | -0.07M |
| Change to operating activities | - | - | - | - | -0.09M |
| Net income | 0.09M | 0.22M | -0.16M | -0.14M | 0.37M |
| Change in cash | 0.89M | 0.56M | -0.31M | 0.05M | -0.11M |
| Begin period cash flow | 0.73M | 0.16M | 0.47M | 0.42M | 0.53M |
| End period cash flow | 1.62M | 0.73M | 0.16M | 0.47M | 0.42M |
| Total cash from operating activities | -0.06M | -0.08M | -0.23M | 0.21M | 0.03M |
| Issuance of capital stock | 0.00M | 1.13M | 0.00M | - | 0.00M |
| Depreciation | 0.14M | 0.06M | 0.08M | 0.11M | 0.07M |
| Dividends paid | 0.00M | 0.00M | 0.00M | - | 0.00M |
| Change to inventory | -0.06M | -0.06M | -0.03M | 0.02M | -0.02M |
| Change to account receivables | 0.04M | -0.43M | -0.02M | 0.17M | -0.24M |
| Change to netincome | - | - | - | - | -0.04M |
| Capital expenditures | 0.47M | 0.20M | 0.04M | 0.07M | 0.06M |
| Change in working capital | -0.23M | -0.21M | -0.05M | 0.21M | -0.37M |
| Stock based compensation | 0.12M | 0.05M | 0.03M | 0.02M | 0.05M |
| Other non cash items | -0.10M | -0.03M | 0.08M | 0.01M | -0.09M |
| Free cash flow | -0.53M | -0.28M | -0.27M | 0.14M | -0.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IOT Innovotech Inc |
-0.01 7.14% |
0.07 | - | - | 2.28 | 2.88 | 1.96 | 33.59 |
| SHRX Sharp Therapeutics Corp. |
- -% |
1.37 | - | - | - | 32.37 | - | - |
| NRX NurExone Biologic Inc. |
-0.01 2.00% |
0.49 | - | 6.90 | - | 15.26 | - | -7.24 |
| MIR MedMira Inc |
- -% |
0.06 | - | - | 223.37 | - | 293.42 | -80.03 |
| TTI Thiogenesis Therapeutics Corp. |
- -% |
0.63 | - | - | - | 15.17 | - | -58.16 |
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. James Timourian Ph.D. | Chairman, CEO, Pres & Sec. | NA |
| Mr. Alan C. Savage | CFO & Director | 1943 |
| Dr. Tyler Boone | Chief Operating Officer | NA |
| Dr. Patricia Nadworny | Chief Scientific Officer and Quality & Safety Director | NA |
| Dr. Merle Olson | Scientific Consultant | NA |
| Dr. James Timourian Ph.D. | Chairman & Secretary | NA |
| Dr. Craig Milne B.Sc., M.B.A., Ph.D. | President, CEO & Director | NA |
| Mr. Bernard Grobbelaar C.A., CPA, CA, CPA | Chief Financial Officer | NA |
| Dr. Tyler Boone Ph.D. | Chief Operating Officer | NA |
| Dr. Patricia Nadworny P.Eng., Ph.D. | Chief Scientific Officer and Quality & Safety Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.